Stocks
GlaxoSmithKline (GSK) R&D US GAAP (year values) |
|||||||||
| 2021 | 2022 | 2022 | 2023 | 2023 | LTM ? | CAGR 5 years ? | |||
| R&D, £ | 5 278 000 000 | 5 488 000 000 | 5 488 000 000 | 6 221 000 000 | 5 245 000 000 | 7 046 000 000 | |||
| Changes by years, y/y, % | 0% | +4% | 0% | +13% | -16% | +6.1% | |||
GlaxoSmithKline. R&D, £
GlaxoSmithKline. R&D, changes, %
GlaxoSmithKline. R&D, sum by quarters, £
GlaxoSmithKline (GSK) R&D US GAAP (quarter values) |
||||||||
| 2023Q2 | 2023Q3 | 2023Q4 | 2023Q4 | 2024Q1 | LTM ? | |||
| R&D, £ | 1 341 000 000 | 1 575 000 000 | 2 049 000 000 | 2 049 000 000 | 1 373 000 000 | 7 046 000 000 | ||
| Changes by years, y/y, % | +8% | +17% | +14% | +14% | +9% | |||
| Changes by quarters, q/q, % | 0% | +17% | +30% | 0% | -33% | |||
